Easy Access to Smoking Cessation for People Receiving Opioid Agonist Therapy Who Are Smoking Tobacco
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Background: About 85% of those receiving opioid agonist therapy (OAT) for opioid dependence
are smoking tobacco. Cigarette smoke lead to lunge diseases and cause illness and death
within this group. BAReNikotin is a multicentre randomised controlled clinical trial that
will test if integration of smoking cessation therapy to clinical practice at OAT-clinics
will increase the rate of OAT-patients that quit smoking.
Intervention: The patients selected for the intervention arm will receive smoking cessation
therapy including weekly brief behavioural interventions and prescription-free nicotine
replacement products such as nicotine lozenges, patches and chewing gum for at least 16
weeks. This will be compared to a group of patients, who does not receive any help to quit
smoking, apart from intial screening of smoking behaviour and advice on where to buy nicotine
replacement products.
The patients will have to attend OAT outpatient clinics in Bergen and Stavanger, Norway. The
main evaluation will take place 16 weeks after the start of the study.
Study population: The target group will be patients with severe opioid dependence receiving
OAT from outpatient clinics in the aforementioned cities who are smoking tobacco daily.
Expected outcome: The primary goal of the study is to see how many of those patients that are
offered smoking cessation treatment, that have stopped smoking or reduced the number of
cigarettes smoked by at least one half by the end of the intervention. We will also
investigate if quitting smoking changes the well-being, physical fitness and quality of life
of the participants. If the nicotine replacement therapy is safe and efficacious, it can be
considered for further scale-up.
Phase:
N/A
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
Helse Stavanger HF Helse Vest University of Bergen